DLRC

What DLRC does

DLRC Ltd is a UK-headquartered regulatory affairs and market access consultancy serving the global life-sciences industry, founded in 2005 by CEO Dianne Lee in Letchworth Garden City. The firm supports medicines (small molecules, biologics, advanced therapy products), medical devices, and combination products across the full lifecycle — from nonclinical and clinical development through marketing authorisation (NDA/BLA/MAA, 510(k)/De Novo/PMA) and post-licensing obligations including PBRERs, variations, and divestments. Service lines are organised into medicines regulatory services, medical devices regulatory services, medical and scientific writing, regulatory submissions management (eCTD publishing via a validated 21 CFR Part 11 / Annex 11 eDMS used by the FDA), business support and due diligence, EU/UK/US representative services (legal representative, MAH, ODD sponsor, UK Responsible Person, US Agent), HTA and market access, and the Regulatory Catalyst — fixed-price packages for startups. Engagement models range from ad-hoc strategic opinions to fully outsourced regulatory affairs teams, with embedded consultants on long-term programmes.

DLRC operates from three wholly-owned entities: DLRC Ltd (UK, headquarters), Orphix Consulting GmbH (Munich, acquired 2020), and DLRC Incorporated (Cambridge/Boston, established 2023), giving it an integrated UK/EU/US footprint and the legal capacity to act as EU/UK representative and US Agent. The team of 80+ professionals includes former EMA CTIS Business team members and alumni of Roche, Pfizer, Mylan, Gilead, Cephalon, and Quintiles/IQVIA. The firm has served 130+ companies — including a Top 5 global pharma (70+ programs over 5+ years) and multiple biotechs whose regulatory support contributed to multi-billion-dollar acquisitions — and is certified ISO 9001, Cyber Essentials, and B Corp (93.4 B Impact Score), with three UK royal honours for International Trade (2017, 2021, 2024).

The business model is professional services with bespoke consulting (time-and-materials, multi-year engagements) as the primary revenue engine, complemented by fixed-price startup packages (Regulatory Catalyst) and recurring lifecycle work (post-licensing, renewals, PBRERs). GTM is senior-led direct sales with no channel partners or resellers, supported by thought-leadership content, industry events, and strategic memberships in RAPS, TOPRA, BIA, ABPI, HKSTP, BIG Incubator, and BioPartner. The company is privately held by founder Dianne Lee with no disclosed external funding, having grown organically and through the single 2020 acquisition.

Name

DLRC

Legal name

DLRC Ltd

Website

https://dlrcgroup.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

DLRC is a UK-headquartered regulatory affairs and market access consultancy serving the global life-sciences industry with 80+ professionals across UK, EU, and US offices, supporting medicines, medical devices, and biotech products from development through post-licensing.

Ownership category

akta.pro rank

Product category

Regulatory Affairs Consulting

NAICS

Professional, Scientific, and Technical Services (541), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regulatory Operations & Publishing (eCTD, RIM, Submission Management) (HLAGAKAC)

akta.pro secondary industry

CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC) (HLAGAKAB)

Keywords

• Regulatory affairs consulting
• Medical device compliance
• Clinical trial regulation
• Marketing authorisation services
• Market access support

Headquarters

HQ city

Letchworth

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Regulatory Affairs Consulting Services: DLRC provides regulatory affairs consulting services supporting medicines, medical devices, and biotech products across the full product lifecycle. Services include regulatory strategy, document preparation, submissions management, and post-licensing support. The company serves clients from startups to large multinationals with flexible engagement models from ad-hoc support to fully outsourced regulatory affairs teams.
2. Regulatory Submissions Management: DLRC's Regulatory Operations team manages global regulatory submissions including eCTD compilation and publishing. The team brings over 75 years of combined experience in managing regulatory submissions across global regions including FDA, EMA, MHRA, SwissMedic, and Health Canada.
3. The Regulatory Catalyst (Startup Packages): Transparent, value-driven service packages delivering expert regulatory guidance to startups. Includes Scope Session, Strategy Workshop, Structure Report, Showcase Pitch Deck, and Complete Catalyst Package. Fixed-price packaging for predictable budgeting. Designed to help startups attract investors and accelerate market entry.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

DLRC provides regulatory affairs and market access consulting services to the life sciences industry, spanning medicines (small molecules, biotech, advanced therapy products) and medical devices across the full product lifecycle — from development and clinical trial regulation through marketing authorisation and post-licensing. Core deliverables include regulatory strategy and gap analysis, dossier authoring and medical/scientific writing, eCTD submissions management, EU/UK/US representative services, HTA and market access support, and dedicated startup-focused Regulatory Catalyst packages.

Product overview

DLRC is a global regulatory affairs and market access consultancy offering a comprehensive portfolio of services for the life sciences industry. The core offering spans medicines regulatory services (development through post-licensing), medical devices regulatory services (development through post-market surveillance), Medical and Scientific Writing, Regulatory Submissions Management/Operations, Business Support and Due Diligence, Representative Services, HTA & Market Access Support, and The Regulatory Catalyst (startup-focused packages). Services are delivered across UK, EU (Germany), and US offices with over 80 professionals providing flexible support from single-issue consulting to fully outsourced regulatory affairs team augmentation.

Differentiator

Problem solved

Functional benefit

Products and services

• Medicines Regulatory Services

Quantifiable outcome

• 25 major regulatory submissions delivered from mid-2020 to end of 2024
• +6 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Twelve partnerships are on record, tiered core and minor.

• RAPS (Regulatory Affairs Professional Society)coreStrategic or Co-development PartnerEnterprise membership connecting DLRC with the largest global organisation of professionals involved with regulatory and quality for healthcare products. Their network includes medical devices, pharmaceuticals and biologics, diagnostics, and digital health.
• TOPRA (The Organisation for Professionals in Regulatory Affairs)coreStrategic or Co-development PartnerTOPRA membership underscores DLRC's investment in professional excellence and regulatory expertise. DLRC provides TOPRA memberships for all regulatory affairs staff, demonstrating commitment to professional development. DLRC staff have won multiple TOPRA Awards for Regulatory Excellence (2021, 2024, 2025).
• HKSTP (Hong Kong Science and Technology Parks Corporation)coreStrategic or Co-development PartnerPartnership allows DLRC to offer global regulatory services to over 2000 park companies in Hong Kong. Through this partnership, DLRC contributes expertise and opens doors for promising startups, especially in life sciences and medtech sectors.
• BIA (Bioindustry Association)minorStrategic or Co-development PartnerBIA provides DLRC a platform to engage with the broader bioindustry ecosystem and contribute to regulatory excellence. DLRC is involved with the PULSE initiative, strategically guiding emerging companies through regulatory pathways.
• ABPI (Association of the British Pharmaceutical Industry)minorStrategic or Co-development PartnerAffiliate membership ensures DLRC team remains well-informed about policy developments and environmental changes affecting clients. Membership provides valuable insights from ABPI meetings with governmental officials, NHS representatives, and other stakeholders.
• BioPartnerminorChannel Partner/ Reseller/ DistributorThrough BioPartner, DLRC enhances international presence and connectivity in the life sciences sector. BioPartner provides practical support for global business development and helps leverage strategic alliances with international organisations and suppliers.
• PING (Pharmaceutical Industry Networking Group)minorStrategic or Co-development PartnerPING membership cultivates valuable professional connections that enhance regulatory solutions and industry awareness. Membership provides diverse perspectives that inform client-focused strategies.
• ConexenminorStrategic or Co-development PartnerConexen unites professionals and founders in Biopharma, Life Sciences, Medical Devices, and Health Tech. DLRC shares commitment to fostering connections and driving positive change.
• BioUKminorStrategic or Co-development PartnerBioUK's network of over 500 member companies provides DLRC access to a diverse community of over 10,000 life sciences professionals across the UK. Membership provides networking, partnering, collaborative innovation opportunities, and specialised training and advisory services.
• One NucleusminorStrategic or Co-development PartnerMembership connects DLRC with the vibrant life sciences and healthcare community headquartered in Cambridge, UK. Participation contributes to a collaborative ecosystem that drives innovation and knowledge sharing throughout the region.
• BIG Incubator (Guangzhou International Bio-Island)minorStrategic or Co-development PartnerPartnership connects DLRC with China's dynamic life sciences ecosystem. BIG supports overseas companies with tailored pathways into the Chinese market, while DLRC provides regulatory strategy and market access expertise to help innovators navigate EU, UK, and US requirements.
• Medilink MidlandsminorStrategic or Co-development PartnerMembership connects DLRC to the thriving life sciences and medtech community across the Midlands and East of England. Leverages innovation support services to stay at the forefront of industry developments and contribute to collaborative initiatives.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Voisin Consulting Life Sciences (VCLS): VCLS is a global regulatory, HTA, and market access consultancy serving biotech, pharma, and medical device clients across US, EU, and emerging markets — directly comparable to DLRC's combined regulatory and HTA & Market Access service portfolio.
• PharmaLex (now part of Cencora): PharmaLex is one of the largest dedicated regulatory affairs and scientific consultancy services providers globally, offering regulatory strategy, submissions management, and lifecycle support across pharma and biotech — highly comparable to DLRC's core service portfolio, though materially larger in scale.
• Arriello Group: Arriello is a regulatory affairs and pharmacovigilance consultancy focused on helping pharma and biotech clients navigate complex EU and global regulatory pathways, including MAA preparation and lifecycle management — directly comparable to DLRC's medicines regulatory services.
• Regulis: Regulis is a UK-based regulatory affairs consultancy providing EU and global regulatory strategy, MAA support, and lifecycle management for pharma and biotech — a directly comparable specialist competitor to DLRC, particularly in the SME segment.
• Inspired Pharma Services: Inspired Pharma Services is a UK-based regulatory affairs consultancy offering services from clinical trial applications through to marketing authorisation and post-licensing — a directly comparable smaller-scale specialist competitor to DLRC's medicines regulatory offerings.

Broad incumbents

• IQVIA: IQVIA is a global clinical and commercial services giant with a substantial regulatory affairs and compliance practice, offering integrated regulatory, clinical, and technology services to large pharma — a broader incumbent that competes with DLRC for enterprise regulatory work.
• Parexel: Parexel is a major global CRO with dedicated regulatory consulting and submissions management capabilities servicing large pharma and biotech — a broader incumbent competitor for end-to-end regulatory programs where DLRC is engaged.
• ICON plc: ICON is a leading global CRO with regulatory affairs services bundled into its clinical and commercialisation offerings, providing enterprise pharma with full-service regulatory support — a broader incumbent competing with DLRC for large multinational engagements.
• Labcorp Drug Development: Labcorp Drug Development (formerly Covance) is a global CRO with regulatory and biopharmaceutical development services, including submissions support and lifecycle management — a broader incumbent whose regulatory capabilities compete with DLRC for enterprise clients.
• Charles River Laboratories: Charles River provides a broad range of discovery, preclinical, and regulatory services globally, with regulatory affairs and consulting capabilities that overlap with parts of DLRC's service portfolio — a broader incumbent in the life sciences services space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dlrcgroup
• Xx.com/dlrcgroup
• Facebookfacebook.com/dlrcltd1

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DLRC